source
- Roche partners with China's Simcere Zaiming on $1.5 billion T-cell engager for B-cell diseasesRoche announced a licensing agreement with Simcere Zaiming, a subsidiary of China's Simcere Pharmaceutical Group, to develop a trispecific T-cell engager called SIM0660. The deal includes an upfro…
- Novartis reports positive multiple sclerosis results with its BTK inhibitorNovartis announced that its BTK inhibitor has shown a positive outcome in a multiple sclerosis study, marking a notable advance for the company in this therapeutic area. The result highlights the…